Is methenamine hippurate safe for use during pregnancy?

Methenamine Hippurate in Pregnancy

Methenamine hippurate can be used in the last trimester of pregnancy where safety is suggested, but should be avoided in early pregnancy where safety is not established. 1

Safety Profile by Trimester

The FDA drug label provides the clearest guidance on pregnancy use:

• Early pregnancy: Safe use is not established - avoid if possible 1
• Last trimester: Safety is suggested but not definitively proven 1
• Animal studies: No adverse fetal effects were observed in pregnant rats and rabbits 1

Clinical Evidence Supporting Use

While the FDA label is cautious, research data provides reassuring pharmacokinetic information:

• Methenamine crosses the placental barrier, but umbilical cord plasma concentrations remain low, only reaching maternal plasma levels after approximately 4 hours 2
• Amniotic fluid concentrations are low and variable with no correlation to maternal or cord plasma levels 2
• A 1979 study concluded that methenamine "may be safely given to pregnant and lactating women with respect to the wellbeing of the child" 2

Important Contraindications and Precautions

Absolute contraindications that apply regardless of pregnancy status 1:

• Renal insufficiency
• Severe hepatic insufficiency
• Severe dehydration
• Concurrent sulfonamide use (forms insoluble precipitate with formaldehyde)

Laboratory Test Interference

Critical caveat: Methenamine hippurate taken during pregnancy interferes with urine estriol measurements when acid hydrolysis is used, resulting in unmeasurably low values 1. This can be circumvented by using enzymatic hydrolysis instead of acid hydrolysis in the laboratory procedure.

Practical Recommendation Algorithm

1. If UTI prophylaxis needed in early pregnancy: Choose alternative agents; methenamine hippurate safety not established
2. If UTI prophylaxis needed in last trimester: Methenamine hippurate is a reasonable option given suggested safety profile
3. Before prescribing at any stage: Verify normal renal and hepatic function, adequate hydration status, and absence of sulfonamide use
4. If prescribed: Alert laboratory about methenamine use if estriol testing is planned

The evidence supports that methenamine hippurate is most appropriately used in the third trimester when the benefit-risk ratio favors treatment, particularly given its antimicrobial-sparing properties that are valuable in the context of rising antibiotic resistance 3, 4.